Company Overview

Nyrada Inc is a new US biotechnology company focusing on innovative, first-in-class, small molecule drugs in non-oncology fields. The Company has a starting pipeline of 3 drug candidates:

NYX-104. A TrpC3 inhibitor for the treatment of excitotoxicity.
NYX-205. A thromboxane synthase inhibitor for the treatment of peripheral neuropathy and ulcerative colitis.
NYX-330. A PCSK9 inhibitor for the treatment of hypercholesterolemia.

  Subscribe to Email Alerts